thank you for the summary:
I just hope when it comes to all these comparisons the company clearly lays out what they mean, so we avoid the 7.2 months fiasco as last data readout. I would assume if they are showing a pfs of 15 months, they will have hard data to support this and not just make a blanket statement, that is our benchmark and not have anything backing it up. The general benchmark statement of 15 months has already been told.
In addition, the dor data has to be understood by everyone, i hope and highly doubt they will have 50% events come end of may to have an actual calculation. If they do, not sure it will look good.
I thought they always used 4th gen best in class. Now they put the word potentially in front of it. but i could be mistaken.
I just hope when it comes to all these comparisons the company clearly lays out what they mean, so we avoid the 7.2 months fiasco as last data readout. I would assume if they are showing a pfs of 15 months, they will have hard data to support this and not just make a blanket statement, that is our benchmark and not have anything backing it up. The general benchmark statement of 15 months has already been told.
In addition, the dor data has to be understood by everyone, i hope and highly doubt they will have 50% events come end of may to have an actual calculation. If they do, not sure it will look good.
I thought they always used 4th gen best in class. Now they put the word potentially in front of it. but i could be mistaken.
Recent BDTX News
- Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 09:19:10 PM
- Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations • GlobeNewswire Inc. • 05/21/2026 09:13:52 PM
- Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC • GlobeNewswire Inc. • 05/19/2026 12:00:00 PM
- Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:20:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:17:30 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2026 08:07:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:03:54 PM
- Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 02:40:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/16/2026 08:12:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 08:03:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:02:04 PM
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/16/2026 08:01:00 PM
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/02/2026 09:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:09:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:33:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2025 01:20:44 PM
- Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM • GlobeNewswire Inc. • 12/03/2025 12:01:00 PM
- Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update • GlobeNewswire Inc. • 12/02/2025 09:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2025 10:20:14 PM
